https://mindmedicinelaw.com/briefing/psychedelics-role-in-social-cognition-new-insights-20260701-18040The Psychedelic Journalen2026-07-01T22:03:11.723956+00:00Psychedelics' Role in Social Cognition: New Insightspsychedelics, social cognition, psychiatric disorders, serotonergic drugs, MDMA, ketamine, clinical trials, therapeutic interventions, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/oregon-psilocybin-program-expansion-sparks-safety-concerns-20260701-18070The Psychedelic Journalen2026-07-01T15:06:03.758509+00:00Oregon Psilocybin Program Expansion Sparks Safety ConcernsOregon psilocybin program, psilocybin safety concerns, psychedelic therapy regulation, Measure 109, psilocybin research, public health policy, therapeutic psilocybin use, psychedelic facilitator traininghttps://mindmedicinelaw.com/briefing/va-initiates-mdma-trial-for-ptsd-in-veterans-20260701-18067The Psychedelic Journalen2026-07-01T15:05:40.960583+00:00VA Initiates MDMA Trial for PTSD in VeteransVA MDMA trial, PTSD treatment, veteran mental health, psychedelic therapy, MDMA-assisted therapy, clinical trial, psychedelic research, veterans affairs, mental health care, post-traumatic stress disorderhttps://mindmedicinelaw.com/briefing/dea-proposes-schedule-i-status-for-4-new-substances-20260701-17986The Psychedelic Journalen2026-07-01T15:05:29.485066+00:00DEA Proposes Schedule I Status for 4 New SubstancesDEA, Schedule I, psychedelic research, controlled substances, drug policy, temporary scheduling, therapeutic potential, regulatory controls, synthetic compounds, psychoactive substanceshttps://mindmedicinelaw.com/briefing/congressional-bill-aims-to-codify-psychedelics-policy-20260701-18068The Psychedelic Journalen2026-07-01T15:05:12.135436+00:00Congressional Bill Aims to Codify Psychedelics Policypsychedelics policy, bipartisan bill, Trump executive order, federal regulation, psychedelic research, industry impact, regulatory framework, mental health, therapeutic benefits, legislative efforthttps://mindmedicinelaw.com/briefing/fda-approval-of-psilocybin-therapy-possible-by-2027-20260701-18069The Psychedelic Journalen2026-07-01T15:04:58.745997+00:00FDA Approval of Psilocybin Therapy Possible by 2027psilocybin therapy, FDA approval, psychedelic medicine, mental health treatment, clinical trials, drug policyhttps://mindmedicinelaw.com/briefing/psilocybin-trials-for-anorexia-in-youth-a-new-frontier-20260630-18062The Psychedelic Journalen2026-07-01T15:05:53.273153+00:00Psilocybin Trials for Anorexia in Youth: A New Frontierpsilocybin, anorexia nervosa, adolescents, clinical trials, psychedelic therapies, mental health, neuroplasticity, FDA, eating disorders, youth interventionshttps://mindmedicinelaw.com/briefing/oregon-psilocybin-center-closure-implications-for-policy-and-market-20260630-17975The Psychedelic Journalen2026-06-30T22:03:23.241416+00:00Oregon Psilocybin Center Closure: Implications for Policy and MarketOregon psilocybin center, psychedelic industry challenges, psilocybin legalization, Oregon Health Authority, regulatory hurdles, psilocybin market implications, operational challenges, psychedelic policy, psilocybin research, federal vs state lawhttps://mindmedicinelaw.com/briefing/ibogaine-s-potential-in-treating-ketamine-use-disorder-20260630-17976The Psychedelic Journalen2026-06-30T22:03:12.214343+00:00Ibogaine's Potential in Treating Ketamine Use Disorderibogaine treatment, ketamine use disorder, addiction therapy, psychoactive compounds, neurotransmitter systems, clinical trialshttps://mindmedicinelaw.com/briefing/acsi-s-dea-application-impact-on-psychedelic-research-20260630-17798The Psychedelic Journalen2026-06-30T15:04:55.275906+00:00ACSI's DEA Application: Impact on Psychedelic ResearchACSI, DEA application, controlled substances import, psychedelic research, clinical trials, supply chain, regulatory compliance, psilocybin, MDMA, public healthhttps://mindmedicinelaw.com/briefing/sacramento-s-psychedelic-use-for-mental-health-trends-and-implications-20260630-17886The Psychedelic Journalen2026-06-30T15:04:36.252142+00:00Sacramento's Psychedelic Use for Mental Health: Trends and Implicationssacramento psychedelics, mental health treatment, self-medication, psychedelic research, regulatory frameworks, psilocybin and MDMA, clinical trials, public health implicationshttps://mindmedicinelaw.com/briefing/definium-s-phase-3-lsd-trial-success-and-industry-impact-20260630-17885The Psychedelic Journalen2026-06-30T15:04:22.430628+00:00Definium's Phase 3 LSD Trial Success and Industry ImpactDefinium, LSD trial, psychedelic medicine, clinical trials, regulatory implications, market dynamics, mental health, FDA, Schedule I substance, therapeutic applicationshttps://mindmedicinelaw.com/briefing/patient-education-in-ketamine-therapies-for-mood-disorders-20260629-18048The Psychedelic Journalen2026-07-01T22:03:19.463321+00:00Patient Education in Ketamine Therapies for Mood Disordersketamine therapy, esketamine treatment, mood disorders, patient education, clinical outcomes, treatment adherence, psychedelic research, mental health, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/psychosocial-protocols-in-psychedelic-therapy-a-scoping-review-20260626-17786The Psychedelic Journalen2026-06-30T15:05:08.927937+00:00Psychosocial Protocols in Psychedelic Therapy: A Scoping Reviewpsychedelic therapy, psychosocial protocols, clinical trials, safety and efficacy, therapeutic guidelines, integration phase, standardization, regulatory approval, therapeutic outcomes, psychedelic experienceshttps://mindmedicinelaw.com/briefing/psychedelics-and-brain-entropy-implications-for-therapy-20260624-17973The Psychedelic Journalen2026-06-30T22:03:32.895208+00:00Psychedelics and Brain Entropy: Implications for Therapypsychedelics, brain entropy, fMRI, neural complexity, therapeutic applications, mental health, clinical trials, neuroscience, psychedelic research, policy implicationshttps://mindmedicinelaw.com/briefing/rethinking-psychiatric-medication-in-bpd-treatment-20260622-17581The Psychedelic Journalen2026-06-30T15:05:34.373514+00:00Rethinking Psychiatric Medication in BPD Treatmentborderline personality disorder, psychiatric medication, biomedical model, mental health treatment, psychopharmacology, patient narratives, symbolic role of medication, relational dynamics, mental health policy, treatment strategieshttps://mindmedicinelaw.com/briefing/opioid-receptor-activation-by-pcp-and-ketamine-structural-insights-20260622-17624The Psychedelic Journalen2026-06-30T15:05:21.911784+00:00Opioid Receptor Activation by PCP and Ketamine: Structural Insightsopioid receptor activation, PCP, ketamine, structural insights, therapeutic potential, safety profiles, neuroscience, clinical trials, public health, translational research